Cost-effectiveness analysis of genetic screening for the Taq1B polymorphism in the secondary prevention of coronary heart disease

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 7, Issue 2, 2007, Pages 119-128

  Kemp, Linda K ^a   Doran, Christopher M ^a   Vos, Theo ^a   Hall, Wayne ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

CETP; Cost effectiveness; Ezetimibe; Pharmacogenetics; Statins; Taq1B polymorphism

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ADULT; AGED; ALLELE; ARTICLE; AUSTRALIA; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; GENE IDENTIFICATION; GENETIC CODE; GENETIC SCREENING; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PRESCRIPTION; PROBABILITY; RESOURCE ALLOCATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SECONDARY PREVENTION;

EID: 34247569484     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.7.2.119     Document Type: Article

References (47)

1. Mathers C, Vos T, Stevenson C. The Burden of Disease and Injury in Australia. Australian Institute of Health and Welfare, Canberra, Australia, cat. no. PHE 17 (1999).
2. Australian Institute of Health and Welfare. Heart, stroke and vascular diseases - Australian facts 2004. In: Cardiovascular Disease Series No. 22. Australian Institute of Health and Welfare, Canberra (2004).
3. Australian Institute of Health and Welfare. Health System Expenditure on Disease and Injury in Australia, 2000-01. In: Health and Welfare Expenditure Series no. 19. Australian Institute of Health and Welfare, Canberra, Australia (2004).
4. Australian Institute of Health and Welfare. Secondary Prevention and Rehabilitation after Coronary Events or Stroke. Australian Institute of Health and Welfare, Canberra, Australia (2003).
5. Brousseau ME, O'Connor JJ, Ordovas JM et al. Cholesteryl ester transfer protein Taq1 B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency. Arterioscler. Thromb. Vasc. Biol. 22(7), 1148-1154 (2002).
6. Dornbrook-Lavender KA, Pieper JA. Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy. Cardiovasc. Drugs Ther. 17, 75-82 (2003).
7. Mukherjee D, Topol EJ. Pharmacogenomics in cardiovascular disease. Curr Probl. Cardiol. 48(5), 317-347 (2003).
8. Bartter JP, Brewer HB, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein. Arterioscler. Thromb. Vasc. Biol. 23(2), 160-167 (2003).
9. Corella D, Saiz C, Guillen M et al. Association of Taq IB polymorphism. in the cholesteryl ester transfer protein gene with plasma lipid levels in a healthy Spanish population. Atheroclerosis 152(2), 367-376 (2000).
10. Jonsson B. Economics of drug treatment: for which patients is it cost-eflective to lower cholesterol? Lancet 358(9289), 1251-1256 (2001).
11. Riviere M, Wang S, Leclerc C et al. Cost-effectiveness of simvastatin in the secondary prevention ofcoronary artery disease in Canada. Can. Med. Assoc. J. 156(7), 991-997(1997).
12. Kmietowicz Z. UK review finds statins are cost effective in secondary prevention. Br. Med. J. 319(7222), 1390 (1999).
13. Szucs TD, Bertel O, Darioli R et al. Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarctor unstable angina pectoris. An analysis based on the LIPID Study. Schweiz. Rundsch. Med. Prax. 89(18), 745-752(2000).
14. Carlquist JF, Muhlestein JB, Horne BD et al. The cholesteryl ester transfer protein Taq 1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am. Heart J. 146(6), 1007-1014 (2003).
15. Ordovas JM, Cupples LA, Corella D et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk. Arterioscler. Thromb. Vasc. Biol, 20(5),1323-1329 (2000).
16. Australian Government Department of Health and Ageing. Medicare Benefits Schedule Book. Commonwealth Department of Health and Ageing, Canberra, Australia (2003).
17. Australian Government Department of Health and Ageing. Schedule of Pharmaceutical Benifits Effective from I May 2004. Commonwealth Department of Health and Ageing (2004).
18. Australian Government Department of Health and Ageing. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Pratctitioners:. Operative from 1 April 2005. Australian Government Department of Health and Ageing, Canberra, Australia (2005).
19. Australian Prescription Products Guide. Thomas J (Ed.). Australian Pharmaceutical Publishing Company, Victoria, Australia (2003).
20. Dewey HM, Thrift AG, Mihalopoulos C et al. Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 32(10), 2409-2416 (2001).
21. LaRosa JC, He J, Vuppututri S. Effects of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282(24), 2340-2346 (1999).
22. Knuiman MW, Vu HT. Risk factors for stroke mortality in men and women: the Busselton Study. J. Cardiovasc. Risk, 3(5), 447-452 (1996).
23. Knuiman MW, Vu HT. Prediction of coronary heart disease mortality in Busselton, Western Australia: an evaluation of the Framingham, national health epidemiologic follow up study, and WHO ERICA risk scores. J. Epidemiol. Community Health 51(5), 515-519 (1997).
24. Knuiman MW, Vu HT Bartholomew HC. Multivariate risk estimation for coronary heart disease: the Busselton Health Study. Aust. NZJ Public Health 22(7), 747-753 (1998).
25. Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered. with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 107(19), 2409-2415 (2003).
26. Davidson MH, McGarry T, Bettis R et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 40(12), 2125-2134 (2002).
27. Feldman T, Koren M, Insull W Jr et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am. J. Cardiol. 93(12), 1481-1486 (2004).
28. Goldberg AC, Sapre A, Liu J et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin. Proc. 79(5), 620-629 (2004).
29. Kerzner B, Corbelli J, Sharp S et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am. J. Cardiol. 91(4), 418-424 (2003).
30. Melani L, Mills R, Hassman D et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur. Heart J. 24(8), 717-728 (2003).
31. Sager PT, Melani L, Lipka L et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am. J. Cardiol. 92(12), 1414-1418 (2003).
32. Barendregt JJ, Van Oortmarssen GJ, Vos T, Murray CJ. A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul. Health Metr. 1(1), 4 (2003).
33. Vos T, Begg S. Victorian Burden of Disease Study: Mortality. Public Health and Development Division, Department of Human Services, Melbourne (1999).
34. ®ISK [computer program]. Palisade Corporation, New York (2002).
35. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 164(4), 208-211 (1996).
36. Simons LA, Simons J, McManus P, Dudley J. Discontinuation rates for use of statins are high. Br. Med. J. 321(7268), 1084 (2000).
37. Lokuge B, Faunce TA, Denniss R. A Backdoor to Higher Medicine Prices? Intellectual Property and the Australia-US Free Trade Agreement. The Australia Institute, Canberra (2003)
38. Van Venrooij FV, Stolk RP, Banga JD et al. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 26(4), 1216-1331 (2003).
39. Kuivenhoven JA, Jukema JW, Zwinderman AH et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N. Engl. J. Med. 338(2), 86-92 (1998).
40. de Grooth GJ, Zerba KE, Huang SP et al. The cholesterol ester transfer protein (CETP) TaqlB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome. J. Am. Coll. Cardiol. 43(5), 854-857 (2004).
41. Klerkx AH, de Grooth GJ, Zwinderman AH et al. Cholesteryl estertransfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur. J. Clin. Invest. 34(7), 21-28 (2004).
42. Boekholdt SM, Sacks FM, Jukema JW et al. Cholesteryl ester transfer protein Taq1B variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 111(3), 278-287 (2005).
43. Klerkx AHEM, Tanck MWT, Kastelein JJP et al. Haplotype analysis of the CETP gene: not Taq1B, but the closely linked 629C-A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum. Mol. Genet. 12(2), 111-123 (2003).
44. Maitland-van der Zee AH, Klungel OH, Stricker BHC et al. Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting β-hydroxy-β-methylglutaryl coenzyme A reductase inhibitor therapy in men. Pharmacogenetics 14(l), 53-60 (2004).
45. Thrift AG, Dewey HM, Macdonell RA et al. Incidence of the major stroke subtypes: initial findings from the North East Melbourne stroke incidence study (NEMESIS). Stroke 32(8), 1732-1738 (2001).
46. Thrift AG, Dewey HM, Macdonell RA et al. Stroke incidence on the cast coast of Australia: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 31(9), 2087-2092 (2000).
47. Bonita R, Broad J B, Beaglehole R. Changes in stroke incidence and case-fatality in Auckland, New Zealand, 1981-91. Lancet 342(8885), 1470-1473 (1993).